Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

Status:
Completed

Trial end date:
2019-07-30

Target enrollment:

Participant gender:

BAY94-9343 was an antibody-drug conjugate (ADC) directed against the cancer antigen mesothelin on tumor cells.

Phase 1

Bayer

Immunoconjugates
Maytansine